Evidence map›Paper›PMID 31571114›Full record

ArticleJournal of neuro-oncology2019

Increasing value of autopsies in patients with brain tumors in the molecular era.

Jared T Ahrendsen, Mariella G Filbin, Susan N Chi, Peter E Manley, Karen D Wright, Pratiti Bandopadhayay, Jessica R Clymer, Kee Kiat Yeo, Mark W Kieran, Robert Jones and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Jared T AhrendsenDepartment of Pathology, Beth Israel Deaconess Medical Center, Boston, USA.
Mariella G FilbinDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, USA.
Susan N ChiDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, USA.
Peter E ManleyDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, USA.
Karen D WrightDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, USA.
Pratiti BandopadhayayDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, USA.
Jessica R ClymerDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, USA.
Kee Kiat YeoDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, USA.
Mark W KieranDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, USA.
Robert JonesDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, USA.
Hart G LidovDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Boston, MA, 02215, USA.
Keith L LigonDepartment of Pathology, Brigham and Women's Hospital, Boston, USA.
Sanda AlexandrescuDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, USA. Sanda.alexandrescu@childrens.harvard.edu.ORCID http://orcid.org/0000-0001-9246-4184
Dana-Farber Cancer Institute · USBoston Children's Hospital · USB.E. Meyers & Co (United States) · USBeth Israel Deaconess Medical Center · USBrigham and Women's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPediatric brain tumors are associated with high morbidity and mortality, in part due to insufficient understanding of tumor biology. With limited tissue allocation for research from surgical specimens, a key barrier to improving biological understanding, brain tumor autopsies have become an increasingly valuable resource. This study reviews the brain tumor autopsy practice at our institution and describes specific emerging research utilization patterns beyond the clinical autopsy report.

methodsWe performed a retrospective analysis of brain tumor autopsies at Boston Children's Hospital (BCH) between 2007 and 2017 and reviewed their consents, neuropathology reports and final diagnoses. We reviewed the method of tissue triaging for research consented autopsies (bioregistry, frozen and fresh tissue) and documented their specific uses.

resultsNinety-six deaths at BCH were due to brain tumors; 56 autopsies were performed (58.3%), of which 49 (87.5%) were consented for research. Tumor mapping was performed on all cases and tissue was allocated for DNA- and RNA-based sequencing studies (published and ongoing). Three tissue allocations with a postmortem interval of 8 h or less resulted in successful cell lines. Tissue from 14 autopsies was contributed to the National DIPG Registry.

conclusionOur institutional pediatric brain tumor autopsy clinical experience demonstrates the increased utility and wide utilization of autopsy-derived tissue for multiple types of research. These results support the increased efforts to obtain research consent for brain tumor autopsy and active collection of unfixed autopsy material in the molecular era.

Indexed as

AutopsyBiomedical ResearchBrain NeoplasmsChildHumansMedical OncologyRetrospective StudiesAutopsy consentAutopsy-derived cell linesBrain tumor autopsyTissue allocation

Identifiers

PMID31571114
OpenAlexW2978025408

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.